Serum 25-hydroxyvitamin D concentrations and lung cancer risk in never-smoking postmenopausal women.
Cancer Causes Control. 2017 Sep 12. doi: 10.1007/s10552-017-0956-1. [Epub ahead of print]
Cheng TD1, Song X2, Beresford SAA2, Ho GYF3,4, Johnson KC5, Datta M6, Chlebowski RT7, Wactawski-Wende J8, Qi L9, Neuhouser ML2.
Abstract mentions a trend toward less benefit from Vitamin D if Vitamin A and/or Calcium
- Smoking reduces vitamin D
- Lung Cancer patients were 2.4 times more likely to have a poor Vitamin D Receptor gene – July 2017 poor VDR ==> low vitamin D ==> Cancer
- Cancer - Lung category listing has
35 items along with related searches
Pages listed in both of the categories Lung Cancer and Vitamin A
- Lung cancer 24 percent less likely if high vitamin D (never-smoking senior women) – Sept 2017
- Lung Cancer reduced by combination of Vitamins D and A – March 2014
- Less Lung Cancer if take more than 800 IU of vitamin D and never smoke or low vitamin A – Oct 2013
- Vitamin A may hinder vitamin D benefits associated with Lung Cancer – July 2013
- Vitamin D protects against lung cancer unless there is excess vitamin A – July 2012
Vitamin D has been implicated in lowering lung cancer risk, but serological data on the association among never-smoking women are limited. We report results examining the association of serum 25-hydroxyvitamin D [25(OH)D] concentrations with lung cancer risk among female never smokers. We also examined whether the association was modified by vitamin D supplementation and serum vitamin A concentrations.
In the Women's Health Initiative, including the calcium/vitamin D (CaD) Trial, we selected 298 incident cases [191 non-small cell lung cancer (NSCLC) including 170 adenocarcinoma] and 298 matched controls of never smokers. Baseline serum 25(OH)D was assayed by a chemiluminescent method. Logistic regression was used to estimate odds ratios (ORs) for quartiles and predefined clinical cutoffs of serum 25(OH)D concentrations.
Comparing quartiles 4 versus 1 of serum 25(OH)D concentrations, ORs were 1.06 [95% confidence interval (CI) 0.61-1.84] for all lung cancer, 0.94 (95% CI 0.52-1.69) for NSCLC, and 0.91 (95% CI 0.49-1.68) for adenocarcinoma.
Comparing serum 25(OH)D ≥ 75 (high) versus <30 nmol/L (deficient), ORs were 0.76 (95% CI 0.31-1.84) for all lung cancer, 0.71 (95% CI 0.27-1.86) for NSCLC, and 0.81 (95% CI 0.31-2.14) for adenocarcinoma.
There is suggestive evidence that CaD supplementation (1 g calcium + 400 IU D3/day) and a high level of circulating vitamin A may modify the associations of 25(OH)D with lung cancer overall and subtypes (p interaction <0.10).
In this group of never-smoking postmenopausal women, the results did not support the hypothesis of an association between serum 25(OH)D and lung cancer risk.
PMID: 28900765 DOI: 10.1007/s10552-017-0956-1
406 visitors, last modified 14 Sep, 2017, URL: